54348

Автор(ы): 

Moorkens E. (KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium)
Vulto A. G. (Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands)
Huys I. (KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium)
Dylst P. (KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium)
Godman B. (Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom)
Keuerleber S. (Main Association of Austrian Social Security Institutions, Vienna, Austria)
Petrova G. (Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria,)
Sović-Brkičić L. (Croatian Health Insurance Fund, Zagreb, Croatia)
Slabý J. (State Institute for Drug Control, Prague, Czech Republic)
Dimitrova M. (Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria)
Laius O. (State Agency of Medicines, Tartu, Estonia)
sebesta R. (State Institute for Drug Control, Brno, Czech Republic)
Karr A. (Karr Consultancy Ltd, Hertfordshire, United Kingdom)
Beck M. (OMEDIT Alsace, Agence Régionale de Santé du Grand Est, Strasbourg, France)
Martikainen J. E. (Research Unit, Social Insurance Institution, Helsinki, Finland)
Selke G. (28Wissenschaftliches Institut der AOK (WIdO), Berlin, Germany)
Spillane S. (Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland)
McCullagh L. (Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland)
Trifirò G. (Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy)
Bonanno P. V. (Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom)
Viksna A. (Department of Medicines and Medical Devices, The National Health Service, Riga, Latvia)
Wladysiuk M. (HTA Consulting, Cracow, Poland)
Mota-Filipe H. (Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal)
Kalaba M. (Primary healthcare center Zemun, Belgrade, Serbia)
Bedrač S. M. (Barcelona Health Region, Catalan Health Service, Barcelona, Spain)
Furst J. (Health Insurance Institute, Ljubljana, Slovenia)
Zara C. (Drug Territorial Action Unit, Catalan Health Service, Barcelona, Spain)
Skiöld P. (TLV, Stockholm, Sweden)
Magnusson E. (Department of Health Services, Ministry of Health, Reykjavík, Iceland)
Simoens S. Н. (KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium,)
Bochenek T. (Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland)
Мешков Д. О. (ИПУ РАН, Лаборатория 81)

Автор(ов): 

32

Параметры публикации

Тип публикации: 

Статья в журнале/сборнике

Название: 

Policies for biosimilar uptake in Europe: An overview

DOI: 

10.1371/journal.pone.0190147

Наименование источника: 

  • Plos one

Обозначение и номер тома: 

v.12(12); 2017

Город: 

  • San Francisco

Издательство: 

  • PloS ONE

Год издания: 

2017

Страницы: 

1-17 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746224/pdf/pone.0190147.pdf)
Аннотация
Проведен анализ мероприятий по увеличению использования биоаналагов в медицине в европейских странах. Рассматриваются конкретные меры, направленные на стимулирование назначения биоаналогов в различных странах.

Библиографическая ссылка: 

Moorkens E., Vulto A.G., Huys I., Dylst P., Godman B., Keuerleber S., Petrova G., Sović-Brkičić L., Slabý J., Dimitrova M., Laius O., sebesta R., Karr A., Beck M., Martikainen J.E., Selke G., Spillane S., McCullagh L., Trifirò G., Bonanno P.V., Viksna A., Wladysiuk M., Mota-Filipe H., Kalaba M., Bedrač S.M., Furst J., Zara C., Skiöld P., Magnusson E., Simoens S.Н., Bochenek T., Мешков Д.О. Policies for biosimilar uptake in Europe: An overview // Plos one. 2017. v.12(12); 2017. С. 1-17 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746224/pdf/pone.0190147.pdf).